King Pharmaceuticals KG Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent

Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent at other companies

eBayEBAY

$512M+2.2%

Dominion EnergyD

$622M-6.6%

Keysight TechnologiesKEYS

$217.25M+41.5%

MPLXMPLX

$912M-19.0%

Becton, Dickinson and CompanyBDX

-$37M-123%

Johnson Controls InternationalJCI

$609M+28.8%

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperations.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's income (loss) from continuing operations, net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's income (loss) from continuing operations, net of tax, attributable to parent?: King Pharmaceuticals (KG) reported income (loss) from continuing operations, net of tax, attributable to parent of -$6.95M in Q1 2026.
How has King Pharmaceuticals's income (loss) from continuing operations, net of tax, attributable to parent changed year-over-year?: King Pharmaceuticals's income (loss) from continuing operations, net of tax, attributable to parent decreased by 1664.7% year-over-year, from -$394K to -$6.95M.